Cargando…

DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas

BACKGROUND: Glioma is the most common of all primary brain tumors with poor prognosis and high mortality. The 2016 World Health Organization classification of the tumors of central nervous system uses molecular parameters in addition to histology to redefine many tumor entities. The new classificati...

Descripción completa

Detalles Bibliográficos
Autores principales: Paul, Yashna, Mondal, Baisakhi, Patil, Vikas, Somasundaram, Kumaravel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379538/
https://www.ncbi.nlm.nih.gov/pubmed/28392842
http://dx.doi.org/10.1186/s13148-017-0331-9
_version_ 1782519627174117376
author Paul, Yashna
Mondal, Baisakhi
Patil, Vikas
Somasundaram, Kumaravel
author_facet Paul, Yashna
Mondal, Baisakhi
Patil, Vikas
Somasundaram, Kumaravel
author_sort Paul, Yashna
collection PubMed
description BACKGROUND: Glioma is the most common of all primary brain tumors with poor prognosis and high mortality. The 2016 World Health Organization classification of the tumors of central nervous system uses molecular parameters in addition to histology to redefine many tumor entities. The new classification scheme divides diffuse gliomas into low-grade glioma (LGG) and glioblastoma (GBM) as per histology. LGGs are further divided into isocitrate dehydrogenase (IDH) wild type or mutant, which is further classified into either oligodendroglioma that harbors 1p/19q codeletion or diffuse astrocytoma that has an intact 1p/19q loci but enriched for ATRX loss and TP53 mutation. GBMs are divided into IDH wild type that corresponds to primary or de novo GBMs and IDH mutant that corresponds to secondary or progressive GBMs. To make the 2016 WHO subtypes of diffuse gliomas more robust, we carried out Prediction Analysis of Microarrays (PAM) to develop DNA methylation signatures for these subtypes. RESULTS: In this study, we applied PAM on a training set of diffuse gliomas derived from The Cancer Genome Atlas (TCGA) and identified DNA methylation signatures to classify LGG IDH wild type from LGG IDH mutant, LGG IDH mutant with 1p/19q codeletion from LGG IDH mutant with intact 1p/19q loci and GBM IDH wild type from GBM IDH mutant with an accuracy of 99–100%. The signatures were validated using the test set of diffuse glioma samples derived from TCGA with an accuracy of 96 to 99%. In addition, we also carried out additional validation of all three signatures using independent LGG and GBM cohorts. Further, the methylation signatures identified a fraction of samples as discordant, which were found to have molecular and clinical features typical of the subtype as identified by methylation signatures. CONCLUSIONS: Thus, we identified methylation signatures that classified different subtypes of diffuse glioma accurately and propose that these signatures could complement 2016 WHO classification scheme of diffuse glioma. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-017-0331-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5379538
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53795382017-04-07 DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas Paul, Yashna Mondal, Baisakhi Patil, Vikas Somasundaram, Kumaravel Clin Epigenetics Research BACKGROUND: Glioma is the most common of all primary brain tumors with poor prognosis and high mortality. The 2016 World Health Organization classification of the tumors of central nervous system uses molecular parameters in addition to histology to redefine many tumor entities. The new classification scheme divides diffuse gliomas into low-grade glioma (LGG) and glioblastoma (GBM) as per histology. LGGs are further divided into isocitrate dehydrogenase (IDH) wild type or mutant, which is further classified into either oligodendroglioma that harbors 1p/19q codeletion or diffuse astrocytoma that has an intact 1p/19q loci but enriched for ATRX loss and TP53 mutation. GBMs are divided into IDH wild type that corresponds to primary or de novo GBMs and IDH mutant that corresponds to secondary or progressive GBMs. To make the 2016 WHO subtypes of diffuse gliomas more robust, we carried out Prediction Analysis of Microarrays (PAM) to develop DNA methylation signatures for these subtypes. RESULTS: In this study, we applied PAM on a training set of diffuse gliomas derived from The Cancer Genome Atlas (TCGA) and identified DNA methylation signatures to classify LGG IDH wild type from LGG IDH mutant, LGG IDH mutant with 1p/19q codeletion from LGG IDH mutant with intact 1p/19q loci and GBM IDH wild type from GBM IDH mutant with an accuracy of 99–100%. The signatures were validated using the test set of diffuse glioma samples derived from TCGA with an accuracy of 96 to 99%. In addition, we also carried out additional validation of all three signatures using independent LGG and GBM cohorts. Further, the methylation signatures identified a fraction of samples as discordant, which were found to have molecular and clinical features typical of the subtype as identified by methylation signatures. CONCLUSIONS: Thus, we identified methylation signatures that classified different subtypes of diffuse glioma accurately and propose that these signatures could complement 2016 WHO classification scheme of diffuse glioma. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-017-0331-9) contains supplementary material, which is available to authorized users. BioMed Central 2017-04-04 /pmc/articles/PMC5379538/ /pubmed/28392842 http://dx.doi.org/10.1186/s13148-017-0331-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Paul, Yashna
Mondal, Baisakhi
Patil, Vikas
Somasundaram, Kumaravel
DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas
title DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas
title_full DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas
title_fullStr DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas
title_full_unstemmed DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas
title_short DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas
title_sort dna methylation signatures for 2016 who classification subtypes of diffuse gliomas
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379538/
https://www.ncbi.nlm.nih.gov/pubmed/28392842
http://dx.doi.org/10.1186/s13148-017-0331-9
work_keys_str_mv AT paulyashna dnamethylationsignaturesfor2016whoclassificationsubtypesofdiffusegliomas
AT mondalbaisakhi dnamethylationsignaturesfor2016whoclassificationsubtypesofdiffusegliomas
AT patilvikas dnamethylationsignaturesfor2016whoclassificationsubtypesofdiffusegliomas
AT somasundaramkumaravel dnamethylationsignaturesfor2016whoclassificationsubtypesofdiffusegliomas